These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 11951839)

  • 21. Gilead sciences releases Viread.
    Giles C
    Surviv News (Atlanta Ga); 2002 Jan; ():15. PubMed ID: 11870987
    [No Abstract]   [Full Text] [Related]  

  • 22. Atazanavir (Reyataz): new recommendations if combined with tenofovir (Viread) -- and warning on Viagra, Cialis, and Levitra.
    AIDS Treat News; 2004 Mar; (399):5. PubMed ID: 15199867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention trials starting.
    AIDS Patient Care STDS; 2004 Jun; 18(6):366-7. PubMed ID: 15384199
    [No Abstract]   [Full Text] [Related]  

  • 24. Would switching the protease inhibitors (PI) to tenoforvir be an option in controlling hypertriglyceridaemia secondary to PIs? A case report.
    Alcaide ML; Kolber M; Jayaweera D
    Int J STD AIDS; 2002 Nov; 13(11):795-6. PubMed ID: 12437905
    [No Abstract]   [Full Text] [Related]  

  • 25. Editorial comment: a tale of two viruses.
    Dieterich DT
    AIDS Read; 2002 Oct; 12(10):448-9. PubMed ID: 12408102
    [No Abstract]   [Full Text] [Related]  

  • 26. New uses for tenofovir: more questions about d4T.
    Proj Inf Perspect; 2003 Jan; (35):15-6. PubMed ID: 12647676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High rate of virologic failure with once-daily ddI/3TC/TDF.
    IAPAC Mon; 2003 Nov; 9(11):279. PubMed ID: 14989185
    [No Abstract]   [Full Text] [Related]  

  • 28. [First nucleotide analog against HIV. Lowers viral load also in drug resistance].
    MMW Fortschr Med; 2002 Aug; 144(33-34):60-1. PubMed ID: 12380157
    [No Abstract]   [Full Text] [Related]  

  • 29. French investigators warn of LPV/TDF/ddI interaction.
    Carter M
    IAPAC Mon; 2003 Dec; 9(12):315. PubMed ID: 15055164
    [No Abstract]   [Full Text] [Related]  

  • 30. Tenofovir helps beat hepatitis B.
    TreatmentUpdate; 2003 Jan; 15(1):4. PubMed ID: 12630369
    [No Abstract]   [Full Text] [Related]  

  • 31. Generic Truvada approved.
    AIDS Patient Care STDS; 2009 May; 23(5):395. PubMed ID: 19422066
    [No Abstract]   [Full Text] [Related]  

  • 32. [Further indications for tenofovir].
    Dtsch Med Wochenschr; 2003 Sep; 128(39):2037. PubMed ID: 14565207
    [No Abstract]   [Full Text] [Related]  

  • 33. [Tenofovir--a new option for combination therapy].
    Polk B
    Med Monatsschr Pharm; 2002 Apr; 25(4):140-1. PubMed ID: 12017127
    [No Abstract]   [Full Text] [Related]  

  • 34. Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization.
    Kagan RM; Merigan TC; Winters MA; Heseltine PN
    Antivir Ther; 2004 Oct; 9(5):827-8. PubMed ID: 15535422
    [No Abstract]   [Full Text] [Related]  

  • 35. Anti-HIV agents. Tenofovir looks good in initial therapy.
    TreatmentUpdate; 2002 Aug; 14(6):3-5. PubMed ID: 12238450
    [No Abstract]   [Full Text] [Related]  

  • 36. Anti-HIV agents. Tenofovir and Videx (ddi) EC--some caution required.
    TreatmentUpdate; 2002 Aug; 14(6):5. PubMed ID: 12238451
    [No Abstract]   [Full Text] [Related]  

  • 37. [Chronic hepatitis B. Tenofovir--the right choice from the beginning].
    MMW Fortschr Med; 2008 May; 150(21):42-3. PubMed ID: 18575255
    [No Abstract]   [Full Text] [Related]  

  • 38. Expanded access to tenofovir.
    TreatmentUpdate; 2001 Oct; 13(6):1-2. PubMed ID: 11768865
    [No Abstract]   [Full Text] [Related]  

  • 39. [No comparison with NRTI. Tenofovir is robust against resistance trouble].
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():65. PubMed ID: 12043079
    [No Abstract]   [Full Text] [Related]  

  • 40. Encouraging results for tenofovir.
    AIDS Patient Care STDS; 2001 May; 15(5):289. PubMed ID: 11530770
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.